Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32795413&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
A Thermostable mRNA Vaccine against COVID-19 #MMPMID32795413
Zhang NN; Li XF; Deng YQ; Zhao H; Huang YJ; Yang G; Huang WJ; Gao P; Zhou C; Zhang RR; Guo Y; Sun SH; Fan H; Zu SL; Chen Q; He Q; Cao TS; Huang XY; Qiu HY; Nie JH; Jiang Y; Yan HY; Ye Q; Zhong X; Xue XL; Zha ZY; Zhou D; Yang X; Wang YC; Ying B; Qin CF
Cell 2020[Sep]; 182 (5): 1271-1283.e16 PMID32795413show ga
There is an urgent need for vaccines against coronavirus disease 2019 (COVID-19) because of the ongoing SARS-CoV-2 pandemic. Among all approaches, a messenger RNA (mRNA)-based vaccine has emerged as a rapid and versatile platform to quickly respond to this challenge. Here, we developed a lipid nanoparticle-encapsulated mRNA (mRNA-LNP) encoding the receptor binding domain (RBD) of SARS-CoV-2 as a vaccine candidate (called ARCoV). Intramuscular immunization of ARCoV mRNA-LNP elicited robust neutralizing antibodies against SARS-CoV-2 as well as a Th1-biased cellular response in mice and non-human primates. Two doses of ARCoV immunization in mice conferred complete protection against the challenge of a SARS-CoV-2 mouse-adapted strain. Additionally, ARCoV is manufactured as a liquid formulation and can be stored at room temperature for at least 1 week. ARCoV is currently being evaluated in phase 1 clinical trials.
free
free
free
Cell 2020 ; 182 (5): 1271-1283.e16
